Showing results (361-370 of 400) with videos related to

Sort By:
Pageof 40
Biorxiv : the Preprint Server for Biology|May 18, 2026
A Continuum of Atrial Peristalsis Initiates the Bicuspid to Quadricuspid Valve TransitionJing Wang, Aaron L Brown, Peng Zhao, et al.
Journal of the American Society for Mass Spectrometry|September 27, 2023
Development of a PNGase Rc Column for Online Deglycosylation of Complex Glycoproteins during HDX-MSThomas Lambert, Marius Gramlich, Luisa Stutzke, et al.
Life Science Alliance|May 30, 2024
Nanobodies as novel tools to monitor the mitochondrial fission factor Drp1Theresa Froehlich, Andreas Jenner, Claudia Cavarischia-Rega, et al.
Microbiological Research|December 19, 2020
Characterization of Lysinibacillus fusiformis strain S4C11: In vitro, in planta, and in silico analyses reveal a plant-beneficial microbeAlessandro Passera, Marzia Rossato, John S Oliver, et al.
Human Gene Therapy|October 4, 2019
Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System ManufacturingConstanze Radek, Ornellie Bernadin, Katharina Drechsel, et al.
Molecular Therapy. Methods & Clinical Development|March 26, 2021
Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cellsNicole Cordes, Carolin Kolbe, Dominik Lock, et al.
Journal of Cancer Policy|April 30, 2026
Gender representation in international cancer research fundingElise M Garton, Constance Burgod, Tosca Le, et al.
EMBO Reports|December 20, 2021
Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concernTeresa R Wagner, Daniel Schnepf, Julius Beer, et al.
Frontiers in Immunology|October 30, 2024
Making the effect visible - OX40 targeting nanobodies for in vivo imaging of activated T cellsDesiree I Frecot, Simone Blaess, Teresa R Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indicationsLee D Kaiser, Allen S Melemed, Alaknanda J Preston, et al.
Pageof 40